The Global "ENT Devices Market" is expected to grow at a CAGR of 8.3% during the forecasting period (2022-2029).
ENT devices are used to diagnose and treat ear, nose, and throat diseases. Popular ENT products include hearing aid devices, ear tubes, ENT bottles, otoscopes, specula, audio screening equipment, ENT surgical devices, and equipment, hearing implants, voice prosthesis devices and equipment, and nasal splints, which are designed specifically for ENT procedures.
Source: DataM Intelligence Analysis (2022)
The rising number of ENT diseases, the geriatric population, market developments, and public awareness boost the global ENT devices market growth in the forecast period.
The high incidence rate of ENT diseases is fueling the growth of the global ENT devices market.
The high incidence rate of ENT diseases such as otitis media, Otitis externa, and epistaxis, among others, is driving the global ENT devices market growth during the forecast period. For instance, according to the NIH, Otitis media is a global concern and is slightly more expected in males than females. The precise annual number of patients is challenging to specify because of the need for more reporting and incidences across many different geographical regions. But the first risk factor that has the greatest impact on the incidence of otitis media is allergic rhinitis, such that children with allergic rhinitis are 5.20 times more likely to develop otitis media. Also, children with adenoid hypertrophy are 1.15 times more likely to develop otitis media. The extreme incidence of otitis media transpires between six and twelve months of life and drops behind age five. Around 80% of all children will encounter a case of otitis media in their lifetime, and between 80% and 90% of all children will encounter otitis media with an effusion prior to their school age. Otitis media is negligibly more common in grown-ups than children, though it is more typical in explicit sub-populations like those with a childhood past of recurrent OM, cleft palate, immunodeficiency or immunocompromised status, and others.
Similarly, otitis externa is one of the more common diseases in otorhinolaryngological practice and is also frequently encountered in primary and pediatric care. It ranges in severity from a mild infection of the external auditory canal to life-threatening malignant otitis externa. Its correct treatment requires a good understanding of the ear canal's anatomy, physiology, and microbiology. Thus, the mentioned data indicates that the high incidence of ENT disorders promotes market growth in the forecast period.
The high cost of ENT devices will hamper the global ENT devices market growth.
However, the high cost of ENT devices is hampering the global market growth. For instance, according to Healthy Hearing, the world's largest hearing-focused consumer website and clinic directory, the average price of an adult hearing aid is about $2,000-$3,000. It can range from $1,000 to more than $4,000 for each device, depending on the level of technology. OTC hearing aids, which aren't suitable for everyone, have a lower price point.
COVID-19 Impact Analysis
In the early pandemic days, ENT clinicians were at the forefront, bearing the brunt of the exposure to the virus. With the help of guidelines, ENT clinicians ensure protection from the virus. One of the first things done was to form a COVID-19 response team. They developed guidelines that allowed them to perform surgery safely and test the patients before operations. They also started doing "urgent elective procedures" and slowly moved into the elective, which means the non-urgent routine operations. Currently, they are back to nearly regular service with some changes that are for the better. The innovation in the delivery of services has been astounding. They are employing more digital technologies, such as telemedicine, as part and parcel instead of as a replacement. However, the doctor-patient relationship has to continue, and it is needed to examine the insides of the nose, throat, or ear, which can't be done in teleconsultation. Therefore, some parts have to revert to standard patient interaction. But some aspects have improved for the better. Therefore from the data, it is anticipated that COVID-19 had a mixed impact on the global market.
Hearing aids are estimated to grow at the fastest CAGR during the forecast period (2022-2029).
The hearing aids segment is estimated to dominate the global ENT device market throughout the forecast period owing to the increasing introduction of new market products. For instance, in October 2021, Audibel, a health-technology company, introduced Arc-AI, an AI hearing aid, which is programmed to adjust hearing volume automatically and is available in various styles, such as behind-the-ear and completely-in-canal styles. Likewise, in January 2021, Oticon, Inc. launched Oticon More, one of the first hearing aid built with an onboard deep neural network (DNN) for people with mild-to-severe hearing loss. Similarly, in August 2020, GN Hearing launched the ReSound ONE, a revolutionary new hearing aid that solves one of the most enduring challenges for people with hearing loss. Moreover, in February 2022, Oticon, Inc. expanded its hearing aid portfolio to allow even more individuals with hearing loss to experience the benefits of Oticon's advanced BrainHearing technology. The additions include two new Oticon More miniBTE styles that meet the needs of users who prefer small, discreet, behind-the-ear (BTE) options and two new hearing aid families.
Furthermore, the growing number of hearing-disabled individuals contributes to the segment's dominance over the global market. For instance, according to the WHO, more than 5% of the world's population, i.e., 430 million individuals comprising 432 million adults and 34 million children, need restoration to manage their 'disabling' hearing loss. It is projected that by 2050 over 700 million individuals will have disabling hearing loss. Thus, from the data, it is clear that the rising product introduction and the growing number of individuals having disabling hearing loss will ensure the dominance of the hearing aid segment over the global market throughout the forecasted period.
Source: DataM Intelligence Analysis (2021)
The North American market is expected to grow at a high CAGR during the forecast period.
The Hearing Loss Association of America estimated that hearing loss is the third most prevalent condition in older U.S. adults affecting approximately 48 million or 20% of the American population, and 28.8 million U.S. adults could benefit from using hearing aids. Also, according to the U.S. Department of Health and Human Services, roughly 2 to 3 out of every 1,000 births in the United States have a noticeable hearing loss level in one or both ears, and over 90% of deaf children are born to hearing parents about 15% of American adults (i.e., 37.5 million) 18 and over age notice some hearing problem. Age is the most decisive predictor of hearing loss in adults aged 20-69, with the most significant portion of hearing loss in the 60 to 69 age group.
Furthermore, the presence of Govt. and non-Government Organizations spreading awareness and delivering assistance to deaf individuals to acquire the best quality of life illustrations of are the Hearing Loss Association of America, the National Association of Deaf, the Academy of Doctors of Audiology (ADA), the Academy of Rehabilitative Audiology (ARA), the Alexander Graham Bell Association working for Deaf and Hard of Hearing, American Academy of Audiology (AAA) and many more. Moreover, the presence of the most advanced and robust healthcare facilities with better healthcare cost reimbursement policies is fueling the dominance of North America over the global ENT devices market during the forecast period (2022-2029).
Source: DataM Intelligence Analysis (2022)
The growing focus on innovation keeps the global ENT devices market competitive. Medtronic Plc, Atos Medical, American Hearing Systems Inc., Olympus Corporation, Cochlear Ltd, InHealth Technologies, Starkey Laboratories Inc., Siemens Healthcare GmbH, Stryker Corporation, and Welch Allyn are examples of a few key market players. These key players hold the market through acquisitions, product launches, and collaborations. For instance, In February 2022, Medtronic introduced its NuVent Eustachian tube dilation balloon, which gives surgeons an outpatient option for some ear, nose, and throat conditions.
Medtronic plc is Ireland based American medical device company. Medtronic was founded in 1949 and is headquartered in Minneapolis, Minnesota, United States. Medtronics deals with four different businesses: the Minimally Invasive Therapies Group, the Diabetes Group, the Restorative Therapies Group, and the Cardiac and Vascular Group.
The product portfolio of Medtronic, Plc. has StealthStation FlexENT Navigation System: StealthStation FlexENT System is an easy-to-use image-guided surgery system that delivers adjustable hardware characteristics and tiered software functionality.
The global ent devices market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.
Nerve Repair and Regeneration Market